🟢 Edesa Biotech is trading 7.48% up in after-hours trading as EB06 vitiligo study nears recruitment

Edesa Biotech is trading at $5.75 (+7.48%) in after-hours trading, despite an earnings miss, as investors may be responding to completed preparations and first-site activation for the Phase 2 EB06 vitiligo study, with recruitment expected in the coming weeks.

• August 13 earnings showed a $5.4 million net loss and $0.60 per-share loss, while R&D expenses rose to $4.0 million.
• Cash totaled $10.3 million at June 30, 2026, highlighting ongoing funding risk.